C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
AFCG Equity

Advanced Flower Capital

NASDAQ · AFCG

$3.48
-0.53%
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 1/5
47/100 composite
Fundamentals74
Regulatory53
Market15
Editorial30
Composite · trailing 12 months

Advanced Flower Capital earns a Neutral rating, with a 47.4 composite placing AFCG in the Neutral band at low 1/5 conviction. Fundamentals provide the principal support at 74.0, driven by positive revenue growth, full reported gross margin capture, and a strong operating margin. Regulatory contributes a middling 53.0, reflecting balanced jurisdiction posture and limited filing activity, partly offset by the absence of enforcement hits. Editorial registers 30.0 because CIN newsroom coverage produced no recent news or brief activity. Market performance is the decisive drag at 15.0, with the liquidity subscore reflecting no recorded trading volume.

Licensed fundamentals data show year-over-year revenue growth of 10.1%, a 100% gross margin, and a 61.03% operating margin. Those metrics explain the perfect gross-margin and operating-margin subscores, while the revenue-growth subscore remains solid rather than exceptional. Net income was flat at zero, consistent with the stated stable financial condition but leaving earnings conversion below the strength implied by operating profitability. The approximately $65.5 million market capitalization contributes only a 32.6 subscore, limiting the aggregate fundamentals score despite strong margins. Primary regulatory filings show the latest filing dated June 30, 2026, with one event across 90 days and two across 180 days. That cadence produced a 34.4 subscore, while zero enforcement hits supported an 80.0 enforcement result.

The clearest forward catalyst sits within fundamentals, the strongest pillar by a wide margin. Sustained top-line expansion combined with continued gross-margin retention and operating profitability would reinforce the existing earnings profile and increase the influence of the 74.0 fundamentals pillar on the composite. Institutional pricing feeds currently provide no liquidity confirmation, while CIN newsroom coverage supplies no incremental narrative catalyst, leaving execution in licensed fundamentals data as the central valuation driver. Regulatory cadence can add support through more frequent primary regulatory filings, but the present 53.0 score lacks enough strength to offset the market pillar’s weakness. The single most important signal to watch is whether revenue growth accelerates while the 61.03% operating margin remains intact.

Scored: 2026-09-23Valid through: 2026-11-07Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
Corporate DetailsCompany profile
Headquarters
477 S. ROSEMARY AVE., SUITE 301, WEST PALM BEACH, FL, 33401
Phone
561.510.2390
SEC CIK
1822523
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$65.5M
Enterprise value
$157.2M
Price to book
0.36
Price to sales
24.09
Revenue (TTM)
$2.7M
Gross profit (TTM)
$2.7M
Operating margin
61.0%
Profit margin
0.0%
Rev growth YoY
10.1%
Return on equity
-6.9%
Return on assets
-3.7%
EPS (TTM)
$-0.64
EPS est. current year
$1.14
Wall St. target price
$8.00
Dividend per share
$0.35
Dividend yield
11.99%
Shares outstanding
22.8M
Insider ownership
38.3%
Institutional ownership
18.3%
Beta
0.95
GICS sector
Financial Services
GICS industry
Asset Management
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Proxy statement
Latest DEF 14A
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Advanced Flower Capital (AFCG)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Advanced Flower Capital (AFCG), a cannabis-sector equity listed on NASDAQ. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

Analyst average price target $8.0.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Analyst upside 130% detected. (3 bullish signals, 1 bearish signal.)

Bullish and bearish analyst opinions for Advanced Flower Capital (AFCG)

Bullish view. Advanced Flower Capital (formerly AFC Gamma) is a cannabis-focused commercial mortgage REIT with senior-secured lending relationships across US MSOs; bulls model book-value stability and a well-covered dividend supported by senior positions in the operator capital stack.

Bearish view. Bears cite borrower concentration risk, credit-quality sensitivity if MSO balance sheets weaken, and the peer-lender competitive environment which has narrowed spreads as new capital entered cannabis credit.

Live ratings, price targets, and consensus figures for Advanced Flower Capital appear above this summary. Explore analyst coverage across the 326-equity cannabis universe.

Latest price: $3.48 (-0.53%) on NASDAQ.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for AFCG are maintained by Cannabis Investor News and refreshed throughout the trading day.